- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Jayne Hornung: Payers Need More Education on Prescription Digital Therapeutics
Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.
Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.
Transcript
What sorts of education efforts with payers need to be made as more prescription digital therapeutics enter the market?
The Digital Therapeutics Alliance is an organization that their main focus is to educate payers on digital therapeutics, and that has to happen broadly, nationally across all payers. We learned during our survey of payers that many of them were not familiar at all with these digital therapeutics—the names did not ring a bell at all. So, the more we can educate payers on these therapeutics and how they can help the patients, that's what we need to do.
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
